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Lessons in p16 from phylum Falconium
Increasingly, biochemical and genetic evidence indicates that mutations
in the gene encoding p16, an inhibitor of cyclin-dependent kinases,
may play a role in some forms of hereditary and sporadic tumors.
In 1978, Mazia pointed out [1] that a recently evolved
model organism, classified as belonging to the phylum
Falconium, was beginning to occupy a central position in
cell-cycle research. These are animals, he said, "which
use [Falcon] plastic dishes as shells and feed on research
grants". Although they have cell cycles that conform to
the standard G1, S, G2 and M phases, Mazia suspected
that established cell lines could not adequately illuminate
the underlying causal relationships governing cell-cycle
progression. The recent controversies and uncertainties
concerning the biological roles of the p 16 protein
emphasize both the value and limitations of studying the
Falconian cell cycle.
Xiong, Zhang and Beach [2] first drew our attention to
p16 when they discovered that the cyclin D-Cdk4 pro-
tein kinase complex was largely replaced by a p16-Cdk4
complex in transformed cell lines. This was surprising in
light of the fact that cyclin D1 - and so, presumably, its
association with a cyclin-dependent kinase (Cdk) - had
been shown to be essential for cell proliferation [3,4].
But this was just the first of a series of paradoxical obser-
vations concerning p16. Shortly thereafter, the p 16 gene
was cloned using a yeast two-hybrid genetic screen
designed to identify proteins that could bind to Cdk4
[5]. Using recombinant proteins, it was then demon-
strated directly that p16 can compete with the D-type
cyclins for binding to Cdk4, and that the p16-Cdk4
complex is inactive as a protein kinase; p16 is therefore
described as an inhibitor of Cdk4. It had been observed
previously that cyclin D1 is over-expressed in some
tumors [6], and this easily fitted our preconceptions that
constitutive activation of certain cell-cycle regulatory
proteins might contribute to unconstrained cell prolifer-
ation. But how could we explain the fact that p16, an
inhibitor of Cdk4, was over-expressed in some trans-
formed cells while cyclin D1, an activator of Cdk4, was
over-expressed in others?
This question still can not be answered with certainty,
because the biological roles of p16 are not yet fully
understood. One possible resolution of the paradox, is
the idea that elevated p16 expression in tumor cells
results from the inactivation of the retinoblastoma-sus-
ceptibility gene product, Rb [6]. It is thought that Rb
acts as a switch which either prevents or allows cellular
entry into, or exit from, the cell cycle depending upon
the phosphorylation state of Rb. Cyclin D-Cdk4 com-
plexes are likely to be the critical Rb kinases [7], and can
therefore reverse the inhibitory effect of Rb on cell
cycling. In fact, in cell lines lacking functional Rb pro-
tein, neither cyclin D1 nor Cdk4 appears to be necessary
for cell proliferation, implying that phosphorylation of
Rb may be the only essential function of the cyclin
D1-Cdk4 complex [8,9]. If expression of p16 were
dependent upon Rb inactivation, then p16 might be part
of an inhibitory feedback loop that turns down Cdk4
activity as Rb is phosphorylated and inactivated
(although there is very little direct evidence yet to sup-
port this idea). This would allow re-accumulation of
unphosphorylated Rb, resetting the stage for the next
cell cycle (Fig. 1). Hence, stable inactivation of Rb -by
mutation or as a result of its sequestration by viral onco-
proteins - would lead to constitutive but futile p16
over-expression, as was originally observed in trans-
formed cell lines [2].
As predicted by this model (Fig. 1), it has been shown
that over-expression of p16 prevents proliferation of
Rb-positive cells, but does not inhibit proliferation of
Rb-negative cells [10]. The implication of these results is
that p16 normally guards against untimely inactivation of
Rb by Cdk4. Accordingly, loss of p16 could lead to con-
stitutive inactivation of Rb and thereby predispose cells
to inappropriate proliferation. It is now essential to deter-
mine whether the correlation between p16 expression
and Rb activity, which has so far been made only in
tumorigenic cell lines, is also observed in primary cells,
which have not acquired the uncharacterized genetic
changes commonly associated with growth in vitro.
Specifically, it will be important to know whether pri-
mary cells from Rb-/- mutant mice have high p16 ex-
pression, and whether re-introduction of Rb into such
cells specifically reduces p16 expression.
If p16 and Rb are inhibitors of the same growth control-
ling pathway, then loss ofpl6 might have as significant an
impact on tumor progression as does loss of Rb, which
was originally identified through its tumor suppressor
function. The trail leading to the identification of p16 as
a tumor suppressor began with genetic linkage studies on
hereditary melanoma [11], which indicated that segment
p21 of chromosome 9 contained a hereditary melanoma
susceptibility gene, MLM. In addition, other studies
found a high incidence of chromosomal rearrangements
and loss of heterozygosity at 9p21 in many types of spo-
radic tumors (for review see [12]). The simplest hypothe-
sis to explain these findings is that a single important
tumor suppressor gene is located at 9 p21; inherited
mutations in this gene cause predisposition to melanoma,
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Fig. 1. The p16 protein may be part of a
negative feedback loop that regulates
Rb activity. Phosphorylation of Rb is
thought to reverse its inhibitory effect on
cell proliferation. In normal cells, the
level of p16 may control the phos-
phorylation state of Rb by determining
the amount of active cyclin D-Cdk4
complex. Thus, loss of p16 could lead
to constitutive activation of cyclin
D-Cdk4, and thereby to constitutive
inactivation of Rb and indefinite cell
proliferation.
whereas acquired mutations promote more general onco-
genic transformation in a variety of tissues.
Cultured melanoma cell lines were used to map deletions
within the 9p21 chromosomal region and to define a
locus most likely to correspond to the relevant tumor
suppressor gene. The region proved to include the p16
gene [13,14]. This was a potentially profitable discovery
as the gene had been cloned only a few months before
on the basis of pl6's ability to bind to the cyclin-depen-
dent kinase, Cdk4. But deletions in tumor lines define a
region which is usually quite large and hence can contain
more than one gene. Thus, in order to pinpoint the
involvement of a particular gene in tumorigenesis,
tumors must be found in which the gene in question is
inactivated by point mutations rather than large deletions.
When Kamb et al. [13] found both small mutations and
deletions of pl6, not only in melanomas but in a variety
of other tumor cell lines, it looked like the culprit might
have been identified.
At this point, p16 displayed many essential characteristics
of a tumor suppressor gene. First, an inherited syndrome
of tumor susceptibility, in this case, familial melanoma,
was identified. Then, cytogenetic studies of tumor and
normal cells indicated that deletions in chromosome
9p21 segregated within a melanoma pedigree. Exhaustive
mapping identified the p16 gene, located within the
chromosomal region delineated by markers linked to
melanoma susceptibility, and the p16 protein had a func-
tion consistent with its being a tumor suppressor. But a
complication soon arose when there appeared to be sub-
stantially fewer p16 mutations in primary tumor samples
than in cell lines derived from tumors. For example,
Cairns et al. [15] examined the frequency of p1 6 muta-
tions in 75 primary tumors, from tissues including lung,
bladder, kidney, head/neck and brain. All the tumors dis-
played allelic loss on 9p, but only two polymorphisms
and two mutations of p16 were identified [15]. The
authors suggested that an unidentified gene, not p 16, was
the primary target of 9p21 allelic loss in a large number
of non-melanoma primary tumors, and that the high
incidence of p16 loss in cell lines reflected
a secondary event that conferred a growth advantage
on cells in culture. Numerous other reports have also
appeared that question the generality of p16's involve-
ment in sporadic tumors exhibiting allelic loss at 9p21
[16,17]. Kamb et al. [13] had been able to pinpoint
p16 as a tumor suppressor gene because of their careful
work with tumor cell lines, but had their reliance on cell
lines misled them about the prevalence of pl6 mutations
in tumors?
Despite these early doubts, the case for p16 involvement
in both familial and sporadic tumors associated with
mutational change at 9p21 has recently received addi-
tional support. Allelic deletions of 9p21-22 were found
in 85 % of pancreatic adenocarcinomas, and analysis of
pl16 in 27 xenografts and 10 cell lines showed homo-
zygous deletions in 41 % and sequence changes, which
were likely to be inactivating, in another 38 % [18].
Sequencing ofp 16 from primary tumor DNA confirmed
the observed mutations. In other work, p16 was also
found to be mutated in 14/27 esophageal cancers, but
not in the surrounding normal tissue [19].
Most recently, p16 has been analyzed in a large series of
xenografts derived from brain and colorectal tumors [20].
Homozygous deletions of p16 were found in 68 %
(26/38) of glioblastomas, although no point mutations in
the p16 coding region were found in the remaining
tumors that lacked p 16 deletions. No changes in p16 -
either deletions or mutations - were found in other
types of brain (0 out of 19) or colorectal (0 out of 25)
tumor xenografts. The absence ofp 16 point mutations in
glioblastomas might suggest that a gene other than p16
was the true 'target' of the observed deletions. But at
least one deletion appeared to be confined to the p16
gene itself, indicating that its loss may be biologically sig-
nificant. Nevertheless, the low frequency of p16 point
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mutations is at least curious, and possibly discouraging
for supporters of p 16's role as a tumor suppressor. One
intriguing possibility arises from the discovery that pl 6 is
located adjacent to a closely related gene, p 15S, which also
encodes a Cdk4 inhibitor. In all but one glioblastoma,
deletion ofp 16 was accompanied by deletion of p 15 [20].
Thus, the apparent lack of pl 16 point mutations in tumors
may be explained by the fact that the deletions that are
found in tumors would be much more likely to inactivate
both p 15 and pl 16 simultaneously.
There is now strong evidence that at least some heredi-
tary melanomas can be explained by mutations in p 16. In
9/15 families with inherited melanoma linked to 9p21,
six pl 16 mutations were identified that co-segregated with
the occurrence of melanoma [21]. Furthermore, 33/36
family members who had melanomas carried a p 16
mutation, whereas families in which melanoma is linked
to a locus on chromosome lp36 (also implicated in pre-
disposition to melanoma) did not have p 1 6 mutations. In
a similar study, however, Kamb et al. [22] found a much
lower incidence of pl6 mutations in familial melanoma:
p16 was mutated in only 2/11 families with melanoma
linked to the 9p21 locus, although, interestingly, two of
these mutations (Gly 93--Trp and Val 118-Asp) were
also identified in other families [21]. Large germ-line
deletions in p 6 were not found.
There are several potential explanations for the apparent
lack of pl6 mutations in some familial melanomas and in
many tumors containing 9p21 allelic loss. For instance,
there may be another tumor suppressor gene at 9p21,
such as p15. Or the frequency of pl16 mutation or inacti-
vation may have been underestimated. Current efforts at
locating p16 mutations have focused on the coding
regions and splice junctions: it is possible that sequences
outside the coding area, such as those affecting gene
expression, may be mutated. Alternatively, allelic in-
activation by mechanisms other than DNA sequence
alterations could occur, such as DNA methylation. In
addition, the frequency ofp 16 loss may have been under-
estimated because of difficulties in detecting homozygous
pl 16 deletions in primary tumor samples, which are often
contaminated with normal tissue. In fact, the high inci-
dence of p 16 mutations in glioblastomas might have been
missed if not for the use of xenografts (which are devoid
of non-tumor tissue) to aid in detection of homozygous
deletions [20]. Resolution of this issue should be aided
by examining the expression of pl 6 mRNA and protein
in those cases in which coding-sequence mutations can
not be found.
In sum, while the accumulating examples of p 1 6 muta-
tions in tumors provide support for the idea that pl6
plays an important role in some tumors, additional bio-
logical tests would certainly help to make the case even
stronger. The effects of restoring p6 (and/or p15)
expression in tumor cell lines are not yet known; nor has
the phenotype of a p 16 'knock-out' mutant mouse been
described. In addition, as the type of p6 mutations
identified in various tumors increases, a systematic assess-
ment of their effects on pl 6 function will become feas-
ible. One new paradox that has emerged from the tumor
studies is that p 16 and Rb mutations do not predispose to
similar types of tumors. Inherited mutations in p1 6 are
associated with familial melanoma, whereas inherited
mutations in Rb are associated with retinoblastoma. This
is not easy to reconcile with the simple picture of p16
and Rb functioning within one or two steps of each
other along the same biochemical pathway. Some salient
features of this key regulatory pathway, or perhaps the
complete range of p16 functions, may not be easily
appreciated or fully manifest in established cell lines.
Many of the remaining questions about p16 should be
answered as we progress beyond phylum Falconium and
begin to focus on the biological functions of p16 in
different cell types in vivo.
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